Anthem Biosciences Limited · NSE:ANTHEM
Anthem Biosciences — Q2 FY26 Earnings Presentation
13 slides from Anthem Biosciences's earnings presentation, Nov 8, 2025
Slide 1: Exchange filing cover letter for earnings call presentation
Date: November 08, 2025 To, BSE Limited, National Stock Exchange of India Limited 20th Floor, P.J. Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai - 400001. Mumbai – 400 051 BSE Scrip Code: 544449 NSE Scrip Symbol: ANTHEM Subject: Earnings Call Presentati
Slide 2: Anthem Biosciences Limited Investor Presentation
Anthem Biosciences Limited Investor Presentation November 8, 2025
Slide 3: Safe Harbour
Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 4: Consolidated Profit & Loss Statement: Q2FY26 vs Q2FY25 vs Q1FY26 Performance
Consolidated Profit & Loss Statement: Q2FY26 vs Q2FY25 vs Q1FY26 Performance Particulars (₹ Mn) Q2FY26 Q2FY25 YoY Q1FY26 QoQ FY25 Revenue from Operations 5,500 5,250 4.8% 5,402 1.8% 18,446 CRDMO 4,719 4,351 8.5% 4,527 4.2% 15,061 Specialty Ingredients 781 899 -13.1% 875 -10.7% 3,385 Other Income 482
Slide 5: Consolidated Profit & Loss Statement: H1FY26 vs H1FY25 Performance
Consolidated Profit & Loss Statement: H1FY26 vs H1FY25 Performance Particulars (₹ Mn) H1FY26 H1FY25 YoY FY25 Revenue from Operations 10,902 8,636 26.3% 18,446 CRDMO 9,267 7,006 32.3% 15,061 Specialty Ingredients 1,636 1,630 0.4% 3,385 Other Income 710 473 50.2% 857 Total Revenues 11,613 9,109 27.5%
Slide 6: Q2FY26 Consolidated Financial Highlights
Q2FY26 Consolidated Financial Highlights Revenues (₹ Mn) EBITDA1 (₹ Mn) and EBITDA Margins (%age) PAT (₹ Mn) and PAT Margins (%age) 5,250 5,500 40.4% 44.5% 29.3% 29.0% 40.0% 40.0% 30.0% 30.0% 20.0% 20.0% 10.0% 2,661 2,231 10.0% 0.0% 0.0% 1,619 1,734 Q2FY25 Q2FY26 Q2FY25 Q2FY26 Q2FY25 Q2FY26 PBT (₹ M
Slide 7: H1FY26 Consolidated Financial Highlights
H1FY26 Consolidated Financial Highlights Revenues (₹ Mn) EBITDA2 (₹ Mn) and EBITDA Margins (%age) PAT (₹ Mn) and PAT Margins (%age) 10,902 39.9% 41.4% 8,636 40.0% 26.8% 26.6% 40.0% 30.0% 30.0% 4,804 20.0% 20.0% 10.0% 3,634 10.0% 3,092 0.0% 0.0% 2,443 H1FY25 H1FY26 H1FY25 H1FY26 H1FY25 H1FY26 PBT (₹
Slide 8: Financial performance continues to remain strong with robust return profile for Q2FY26
Financial performance continues to remain strong with robust return profile for Q2FY26 ₹5,500 Mn 44.5% 29.0% Strong Business Q2FY26 Revenues Q2FY26 EBITDA Margin Q2FY26 PAT Margin Performance 2,149 / 1,045 324KL 142KL Robust Technology # Employees / Scientific Staff Custom Synthesis Capacity Ferment
Slide 9: Growth momentum of Q1FY26 has continued in Q2FY26, resulting in robust H1FY26 performance
Growth momentum of Q1FY26 has continued in Q2FY26, resulting in robust H1FY26 performance ₹10,902 Mn 41.4% 26.6% Strong Business H1FY26 Revenues H1FY26 EBITDA Margin H1FY26 PAT Margin Performance 56.4% 14 9.8% Platforms across Commercial Molecules R&D Services Commercial Molecules discovery to Contr
Slide 10: Financial Highlights: Q2FY26 and H1FY26
Financial Highlights: Q2FY26 and H1FY26 Quarterly Performance: Consolidated Revenue from Operations was ₹5,500 Mn for the quarter CRDMO business delivered ₹4,719 Mn revenues Specialty Ingredients delivered ₹781 Mn revenues EBITDA was ₹2,661 Mn, with EBITDA margins at 44.5% PAT (Profit Afte
Slide 11: Business Highlights
Business Highlights Capex and Investment Highlights Unit II (Harohalli): Inaugurated the final block of 76 kL custom synthesis capacity at Unit II on 5th Nov, 2025 and commenced commercial operations. With this Unit II expansion has been completed Unit III (NeoAnthem, Harohalli): All blocks
Slide 12: Message from Chairman, MD and CEO
Message from Chairman, MD and CEO “We are pleased to report a robust performance for Q2FY26, driven by our CRDMO revenue stream, which has delivered consistent performance over the past five quarters. Our commitment to continuous improvement, innovation, and responsible business practices remains un
Slide 13: Thank You
Thank You Anthem Biosciences Limited NeoAnthem Lifesciences Private Limited Unit I: No.49, F1 &F2, Canara Bank Road, Unit III: 313-P,314-P, 318-P, Harohalli Bommasandra Industrial Area Phase 1, Industrial Area, Phase II, Bommasandra, Bangalore, 560 099, India Kanakapura Taluk, Ramnagar District, Har